Peter Baum, Ph.D., is Silverback’s vice president of immunology. Dr. Baum has nearly 30 years of research and development experience in the biotechnology industry. He began his career at Immunex, where he played a leadership role in the discovery and development of Enbrel®, a TNF inhibitor approved for the treatment of several autoimmune diseases. After Immunex, he went on to hold research leadership positions at Amgen and Trubion, and was an early consultant to several successful biotechnology companies. Prior to joining Immunex, Dr. Baum was a postdoctoral fellow at the University of Washington. He received his Ph.D. in microbiology from the University of California, Berkeley.